Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Doan's back-pain relief comparative ad claims challenged by FTC.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

DOAN'S PILLS BACK PAIN RELIEF COMPARATIVE AD CLAIMS CHALLENGED BY FTC in a complaint against Ciba Self-Medication issued June 26. The Federal Trade Commission is seeking to impose an order requiring Ciba to "cease and desist" from representing, without "competent and reliable supporting evidence," that Doan's pills are "more effective than other over-the-counter analgesic drugs for relieving back pain or any other kind of pain."

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Recent And Upcoming FDA Advisory Committee Meetings

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

See All
UsernamePublicRestriction

Register

PS085526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By